



Announcement Summary

Entity name

IMAGION BIOSYSTEMS LIMITED

Date of this announcement

Friday December 17, 2021

The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

| ASX +security code | Security description | Total number of +securities to be issued/transferred | Issue date |
|----------------------------------|---|--|------------|
| New class - code to be confirmed | 6,000,000 FY21 Performance Options exercisable at \$0.0872, vesting and expiring on different terms. | 6,000,000 | 14/12/2021 |
| New class - code to be confirmed | 1,500,000 Unlisted Options exercisable at \$0.0872, vesting monthly over 3 years varying expiry dates | 1,500,000 | 14/12/2021 |
| New class - code to be confirmed | 9,000,000 FY21 Performance Rights vesting during a 4 year period subject to performance milestones. | 9,000,000 | 14/12/2021 |

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

IMAGION BIOSYSTEMS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616305027

1.3 ASX issuer code

IBX

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/12/2021

For personal use only



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code ("new class")

For personal use only



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

New +securities issued under an +employee incentive scheme

ASX +security code

New class - code to be confirmed

+Security description

6,000,000 FY21 Performance Options exercisable at \$0.0872, vesting and expiring on different terms.

+Security type

Other

ISIN code

Date the +securities the subject of this notification were issued

14/12/2021

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP | Name of registered holder | Number of +securities |
|-------------------|---------------------------|-----------------------|
| Yalia Jayalakshmi | Yalia Jayalakshmi | 6,000,000 |

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

A summary of the terms of the Employee Incentive Scheme were provided in the Notice of Annual General Meeting announced to the ASX on 19 June 2020
<https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4j96kz.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

6,000,000 Options exercisable at \$0.0872, vesting and expiring:
 -1,000,000 Options will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company secures decision enabling data package from a minimum 12-15 subjects enrolment in the phase 1 clinical study to enable Go/No Go development decision for the MagSense® HER2 product candidate; options will expire on 30 Nov 2025;
 -1,000,000 Options will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company completes the

For personal use only



MH2TR Phase 1 study or submits a regulatory package in the US or EU or another country of interest to expand the current Phase 1 study; options will expire on 30 Nov 2025;
-1,000,000 Options vest on 30 Nov 2022, expire on 30 Nov 2027;
-1,000,000 Options vest on 30 Nov 2023, expire on 30 Nov 2028;
-1,000,000 Options vest on 30 Nov 2024, expire on 30 Nov 2029;
-1,000,000 Options vest on 30 Nov 2025, expire on 30 Nov 2030.
Vesting of the options is subject to continuous employment.

Issue details

Number of +securities

6,000,000

New +securities issued under an +employee incentive scheme

ASX +security code

New class - code to be confirmed

+Security description

1,500,000 Unlisted Options exercisable at \$0.0872, vesting monthly over 3 years varying expiry dates

+Security type

Other

ISIN code

Date the +securities the subject of this notification were issued

14/12/2021

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

A summary of the terms of the Employee Incentive Scheme were provided in the Notice of Annual General Meeting announced to the ASX on 19 June 2020



<https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4j96kz.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

1,500,000 Unlisted Performance Options exercisable at \$0.0872, vesting monthly over 3 years with varying expiry dates between 31 December 2024 and 30 November 2027. The vesting of the options is subject to continuous employment.

Issue details

Number of +securities

1,500,000

New +securities issued under an +employee incentive scheme

ASX +security code

New class - code to be confirmed

+Security description

9,000,000 FY21 Performance Rights vesting during a 4 year period subject to performance milestones.

+Security type

Other

ISIN code

Date the +securities the subject of this notification were issued

14/12/2021

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP | Name of registered holder | Number of +securities |
|-------------------|---------------------------|-----------------------|
| Yalia Jayalakshmi | Yalia Jayalakshmi | 9,000,000 |

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

For personal use only



Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

A summary of the terms of the Employee Incentive Scheme were provided in the Notice of Annual General Meeting announced to the ASX on 19 June 2020
<https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4j96kz.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Vesting conditions:
-1,000,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company submits a regulatory package (IND/IDE/CTA or equivalent) in the US or EU for investigational use of at least one product candidate;
-2,000,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company obtains US or EU regulatory investigational use clearance to proceed to patient enrolment for at least one product candidate;
-2,500,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company achieves a market capitalisation of at least \$250 million for a continuous period of at least 20 trading days; and
-3,500,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company obtains regulatory agreement (FDA/EU or another country of interest) for a pivotal or phase 2b/3 protocol (such as FDA EOP2 meeting minutes).

Issue details

Number of +securities

9,000,000

For personal use only



For personal use only



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

| ASX +security code and description | Total number of +securities on issue |
|-------------------------------------|--------------------------------------|
| IBX : ORDINARY FULLY PAID | 1,121,018,534 |
| IBXOA : OPTION EXPIRING 28-APR-2023 | 233,501,933 |

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|--------------------------------------|
| IBXAAD : OPTION EXPIRING 30-NOV-2026 EX \$0.14 | 1,000,000 |
| IBXAAE : OPTION EXPIRING 30-NOV-2027 EX \$0.14 | 1,000,000 |
| IBXAAF : OPTION EXPIRING 30-NOV-2028 EX \$0.14 | 1,000,000 |
| IBXAW : OPTION EXPIRING 24-JUN-2024 EX \$0.028 | 2,150,000 |
| IBXAX : OPTION EXPIRING 22-AUG-2024 EX \$0.06 | 300,000 |
| IBXAY : OPTION EXPIRING 07-OCT-2024 EX \$0.06 | 200,000 |
| IBXAZ : OPTION EXPIRING 20-SEP-2024 EX \$0.06 | 100,000 |
| IBXAAA : OPTION EXPIRING 01-MAY-2026 EX \$0.028 | 3,250,000 |
| IBXAAB : OPTION EXPIRING 01-MAY-2027 EX \$0.028 | 3,250,000 |
| IBXAAC : OPTION EXPIRING 01-MAY-2028 EX \$0.028 | 2,000,000 |
| IBXAE : PERFORMANCE RIGHTS | 10,000,000 |
| IBXAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 7,150,000 |



| | |
|--|-----------|
| IBXAAG : OPTION EXPIRING 31-MAY-2029 EX \$0.115 | 200,000 |
| New class - code to be confirmed : 6,000,000 FY21 Performance Options exercisable at \$0.0872, vesting and expiring on different terms. | 6,000,000 |
| New class - code to be confirmed : 1,500,000 Unlisted Options exercisable at \$0.0872, vesting monthly over 3 years varying expiry dates | 1,500,000 |
| New class - code to be confirmed : 9,000,000 FY21 Performance Rights vesting during a 4 year period subject to performance milestones. | 9,000,000 |

For personal use only



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

For personal use only